Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cambrium designs and manufactures novel material building blocks using biotechnology and artificial intelligence. Its flagship product NovaColl™—a micro-molecular collagen produced by precision fermentation—is used in skincare. The company also develops plastic-free leather alternatives, natural retinol replacements, hair bonding solutions, and hydrophobic textile coatings. Cambrium’s AI-driven molecular design platform enables rapid development of high-performance sustainable molecules ("Supermolecules™") that outperform traditional chemical ingredients while reducing environmental impact. The company has raised over $13M since its founding in Berlin in 2020 and partners with contract manufacturers to scale production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cambrium.